parasite. Due to the seemingly dispensable role of FV PMs in parasite growth and survival, the
focus of PM‐targeted drug development is shifting towards non‐FV PMs. Selective inhibitors
of PM5 have been developed and shown strong inhibition potency to parasite growth.
On the other hand, our knowledge on PMs is still quite limited and much needs to be clari‐
fied and explored in the future studies. For example, what is the biological meaning of the
presence of four FV PM paralogs in P. falciparum? What do the FV PM inhibitors authenti‐
cally target to exert their anti‐parasitic activity? What are other possible roles of PM5 than
host‐targeted protein export? What are the functions of PMs 6‐10, and can these enzymes be
antimalarial drug targets? What is the likelihood that PMs are used as immunogens in active
immunization and that antibodies directed against PMs are used in passive immunization
to protect hosts from malaria parasite infection? Successful PM‐targeted drug development
replies on a comprehensive understanding of this enzyme family.
List of abbreviations
ACTs artemisinin‐based combination therapies
ALLN N‐acetyl‐Leu‐Leu‐norleucinal
AN artemisinin
BFA brefeldin A
Chr. chromosome
CQ chloroquine
(k)Da (kilo‐)dalton
DDT dichloro‐diphenyltrichloroethane
E. coli Escherichia coli
E‐64 L‐3‐carboxy‐2,3‐trans‐epoxypropionyl‐leucylamido(4‐guanidino)butane
EC 50 half maximal effective concentration
ECM experimental cerebral malaria
EM electron microscopy
ER endoplasmic reticulum
FP falcipain
FV food vacuole
GFP green fluorescence protein
HAP Histo‐Aspartic Proteinase
Hb hemoglobin
hBACE‐1 human β‐secretase 1
hcatD human cathepsin D
202 Natural Remedies in the Fight Against Parasites